Physician profile
Aaron E Fuchs
NPI 1124261177
$375,712.41
in general payments reported to CMS, 2019-2025
41 companies · $83K in 2025
The $83K reported for 2025 was more than what 97% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $23K · 2021: $15K · 2022: $62K · 2023: $100K · 2024: $60K · 2025: $83K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $204K · Food and Beverage: $15K · Consulting Fee: $11K · Travel and Lodging: $8,558 · Honoraria: $3,600 · Education: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $203,921.41 |
| Food and Beverage | $15,487.14 |
| Consulting Fee | $11,082.50 |
| Travel and Lodging | $8,558.28 |
| Honoraria | $3,600.00 |
| Education | $224.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $67,557.58 | 2021-2025 | Opzelura, Opzelura |
| Lilly USA, LLC | $65,232.38 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Dermavant Sciences, INC. | $64,753.65 | 2022-2024 | Vtama |
| Pfizer INC. | $60,375.39 | 2019-2025 | |
| Galderma Laboratories, L.P. | $31,549.81 | 2019-2025 | Nemluvio, Epsolay, Aklief |
| Novartis Pharmaceuticals Corporation | $28,934.26 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15,390.33 | 2019-2025 | Siliq, Jublia, Cabtreo |
| Ucb, INC. | $8,478.35 | 2019-2025 | Bimzelx, Cimzia |
| Journey Medical Corporation | $5,474.15 | 2019-2025 | |
| Genzyme Corporation | $4,891.60 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $4,084.98 | 2019-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $3,920.17 | 2019-2025 | Adbry, Anzupgo |
| Organon LLC | $3,790.82 | 2025 | Vtama |
| Janssen Biotech, INC. | $2,640.69 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Abbvie INC. | $2,462.34 | 2019-2025 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Fuchs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.